IQVIA Holdings, Inc. (IQV) Stock Price & How to Invest

IQVIA Holdings is a healthcare-focused data, analytics, and clinical-research company formed in 2016 from the merger of Quintiles (a large CRO) and IMS Health (a pharmaceutical-data provider). It operates in three segments: Technology & Analytics Solutions, which sells prescription and market data, real-world evidence, and commercial software to drug and device makers; Research & Development Solutions, its clinical research organization arm that designs and runs clinical trials on behalf of pharma and biotech sponsors; and Contract Sales & Medical Solutions. IQVIA makes money from long-duration trial contracts, recurring data and software subscriptions, and consulting, serving essentially all of the top 20 global pharmaceutical companies.

The investment picture is that of a wide-moat compounder tied to the health of global drug development. IQVIA's edge comes from combining one of the industry's deepest proprietary data assets with the operational scale to run trials, which is hard for rivals to replicate. For full-year 2025 the company reported revenue of about $16.3 billion and adjusted diluted EPS of roughly $11.92, and it entered 2026 with a record R&D backlog of about $34.2 billion. Growth is real but cyclical: when biotech funding tightens or large pharma delays programs, trial bookings and RFP flow soften, and the company carries substantial debt that it refinances at higher rates. The bull case now leans heavily on IQVIA layering AI agents onto its data to widen margins.

IQVIA's demand is tied to pharma and biotech R&D budgets, which are cyclical: biopharma funding fell about 20 percent in 2025 to roughly $82 billion as IPOs hit a decade low, and prolonged funding weakness can slow trial starts, RFP flow, and bookings. Large pharma patent cliffs, pricing pressure, and policy changes around drug spending can prompt clients to delay or cancel programs. The company also carries a substantial debt load that it refinances at higher coupons in a higher-for-longer rate environment, which pressures free cash flow and limits strategic flexibility. Competition from ICON and Labcorp in clinical research and Veeva Systems in commercial software is intensifying, and any misstep in converting the large backlog into recognized revenue would weigh on results.

18 analysts publish price targets on IQV, averaging $272.94 against a $235.02 price as of August 2026, or +16.1%. The published targets run from $240.00 to $300.00, a narrow spread, and the ratings split 19 buy, 2 hold, 0 sell. Over the last six months there have been 9 raises and 2 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full IQV forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on IQVIA Holdings, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Record backlog and bookings momentum. IQVIA ended the first quarter of 2026 with a record backlog of about $34.2 billion, of which roughly $8.9 billion is convertible to revenue over the next twelve months, up nearly 8 percent year over year. The most optimistic published target, $300.00, assumes this works close to its best case.

The case against. IQVIA's demand is tied to pharma and biotech R&D budgets, which are cyclical: biopharma funding fell about 20 percent in 2025 to roughly $82 billion as IPOs hit a decade low, and prolonged funding weakness can slow trial starts, RFP flow, and bookings. The most pessimistic target, $240.00, is roughly what IQV is worth if this bites instead.

Read the full bull and bear case on IQV, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see IQVIA Holdings, Inc.'s investor relations page or your broker.

• Revenue (FY2025): ~$16.3 billion
• Adjusted diluted EPS (FY2025): ~$11.92
• Adjusted EBITDA (FY2025): ~$3.8 billion
• Backlog (Q1 2026): ~$34.2 billion
• 2026 revenue guidance: ~$17.15 to $17.35 billion
• Market cap: ~$35 billion

IQVIA reported full-year 2025 revenue of about $16.3 billion with adjusted diluted EPS near $11.92, and issued 2026 revenue guidance of roughly $17.15 to $17.35 billion alongside adjusted EPS guidance of about $12.55 to $12.85. At a mid-2026 share price near $208 and a market cap around $35 billion, the stock traded at a P/E in the high teens to about 20x, a valuation that has compressed from prior years. The record backlog of about $34.2 billion provides visibility, but the pace of backlog-to-revenue conversion and biotech funding trends drive how much of that guidance is realized.

If you want IQV exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

Other names that sit close to IQV: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get IQV exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (BBH), which spreads the position across many companies. Or build it into a focused thematic portfolio, so IQV sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where IQV fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

IQVIA is a high-quality, data-rich pillar of the drug-development supply chain that grows with global pharma R&D and commercial spending, so its trajectory hinges on biotech funding, trial bookings, and how much of its record backlog converts to revenue against a leveraged balance sheet.

Whether IQV is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is IQV a buy or a sell?, and where the stock could go from here in the IQV stock forecast.

For income investors, whether IQV pays a dividend and how the payout looks is covered in does IQV pay a dividend? And to weigh IQV against a peer, read the full side-by-side comparisons: IQV vs ICLR and IQV vs LH.